Join
Live feed
·
PRReleasevia Quantisnow
MannKind Corporation logo

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

ByQuantisnow·Wall Street's wire, on your screen.
MNKD· MannKind Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNKD (MannKind Corporation) and more on Quantisnow.